United Technologies UT AG is a holding company incorporated in Zurich, Switzerland. It is owned by four Swiss corporate shareholders and holds investments in United Cosmeceuticals GmbH. United Technologies UT AG owns several patents on its proprietary biotechnology platform based on interleukin-1 alpha (Dermatopoietin®) and enkephalin analogues with applications in cosmetics, dermatology and other medical fields.
The main objectives of United Technologies UT AG are to further expand the scientific and business opportunities of its patented Dermatopoietin technology, to explore other biotechnological therapeutic approaches e.g. in dermatology and dentistry and to offer OEM and consulting services to the biotech industry.
Dermatopoietin® - I am the architect
Figure: Dermatopoietin is a key regulator of skin and hair renewal with many potential applications in cosmetics, dermatology and dentistry.
| 2007 | United Technologies UT AG founded as an R&D company |
| 2008 | United Cosmeceuticals GmbH founded as a distribution company |
| 2007 - 2009 | Development of Dermatopoietin and Hexadeltine as cosmetic active ingredients |
| 2009 | Launch of EVEN of Switzerland, phased out in 2010 |
| 2010 | Launch of DermatoPoietin, phased out in 2013 |
| 2013 | Restructuring of United Technologies UT AG as holding company and United Cosmeceuticals GmbH as operative company for the entire value chain |
| 2015 | Launch of EVENSWISS® |
